Chronic Pain News and Research

RSS

Deaths from opioid use in Ontario have doubled, according to new study

Deaths from opioid use in Ontario have doubled-from 13.7 deaths per million residents in 1991 to 27.2 deaths per million residents in 2004-according to a new study led by physicians at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES) in Toronto.

8 Dec 2009

Opioids can be a safe and effective treatment for pain, shows study

A study published in the current issue of the Canadian Medical Association Journal (CMAJ) by Dhalla et al. has reviewed opioid-related deaths in Ontario from 1991 to 2004. The Canadian Pain Society (CPS) is very concerned that a small percentage of the population is misusing opioid analgesics, also called narcotic pain killers, resulting in harm and even death.

8 Dec 2009

FDA approves St. Jude Medical's Penta surgical lead for neurostimulation therapy

St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.

4 Dec 2009

FDA approves St. Jude Medical's MultiSteering Technology software for optimizing neurostimulation therapy

St. Jude Medical, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its next-generation MultiSteering Technology software for Rapid Programmer™, a programming platform used to optimize neurostimulation therapy for chronic pain patients.

4 Dec 2009

Phosphagenics commences Phase 1B clinical trial of its oxycodone/TPM transdermal patch systems

Phosphagenics Limited today announced the initiation of a Phase 1B clinical trial for its patented oxycodone/TPM (Targeted Penetration Matrix) transdermal patch systems.

2 Dec 2009

J&JPRD submits an NDA for tapentadol ER tablets

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older.

2 Dec 2009

Increasing patient responsibility in medical decisions may decrease their willingness to accept risky treatment options

A recent study suggests that increasing patient responsibility for making medical decisions may decrease their willingness to accept risky treatment options. Details of this proof-of-concept study appear in the December issue of Arthritis Care & Research, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

30 Nov 2009

XenaCare Holdings becomes national sponsor of Arthritis Foundation

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.

27 Nov 2009

Older adults with chronic musculoskeletal pain face increase risk for falls

Older adults who reported chronic musculoskeletal pain in two or more locations, higher levels of severe pain, or pain that interfered with daily activities were more likely to experience a fall than adults who did not reports these types of pain, according to a study in the November 25 issue of JAMA.

25 Nov 2009

Canadians with chronic neck and back pain now have access to top spinal care

Canadians suffering from chronic and severe neck and back pain now have access to the top spinal care available. Spinal heath expert, Dr. Ron Nusbaum, has launched Back Clinics of Canada, a state-of-the-art facility that focuses on educating patients on the importance of spinal health and offering cutting-edge care that can bring an end to back pain.

25 Nov 2009

Seniors with chronic pain more at risk of falls

Chronic pain is experienced by as many as two out of three older adults. Now, a new study finds that pain may be more hazardous than previously thought, contributing to an increased risk of falls in adults over age 70. The findings appear in the November 25 issue of The Journal of the American Medical Association (JAMA).

24 Nov 2009

Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain

Breast cancer patients treated with the chemotherapy drug Taxol (paclitaxel) are more likely to develop chronic neuropathic pain, according to research published in The Journal of Pain, the peer review publication of the American Pain Society.

24 Nov 2009

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.

23 Nov 2009

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

St. Jude Medical, Inc. announced today that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.

18 Nov 2009

Cancer pain drug market to be $3.7 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the continued dominance of opioids that include immediate-release morphine and novel fast acting opioid reformulations, the cancer pain drug market will increase from $2.3 billion in 2008 to $3.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

17 Nov 2009

FDA approves Par Pharmaceutical's new painkiller drug

Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for the 100mg and 200mg strengths of tramadol ER.

17 Nov 2009

Chronic pain patients with depression three times more likely to receive opioid medications

Chronic pain patients with a history of depression are three times more likely to receive long-term prescriptions for opioid medications like Vicodin compared to pain patients who do not suffer from depression, according to new research.

16 Nov 2009

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

13 Nov 2009

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

Chronic Pain News and Research

Deaths from opioid use in Ontario have doubled, according to new study

Opioids can be a safe and effective treatment for pain, shows study

FDA approves St. Jude Medical's Penta surgical lead for neurostimulation therapy

FDA approves St. Jude Medical's MultiSteering Technology software for optimizing neurostimulation therapy

Phosphagenics commences Phase 1B clinical trial of its oxycodone/TPM transdermal patch systems

J&JPRD submits an NDA for tapentadol ER tablets

Increasing patient responsibility in medical decisions may decrease their willingness to accept risky treatment options

XenaCare Holdings becomes national sponsor of Arthritis Foundation

Older adults with chronic musculoskeletal pain face increase risk for falls

Canadians with chronic neck and back pain now have access to top spinal care

Seniors with chronic pain more at risk of falls

Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain

Raptor Pharmaceutical announces results of NGX426 clinical trial

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

Cancer pain drug market to be $3.7 billion in 2018

FDA approves Par Pharmaceutical's new painkiller drug

Chronic pain patients with depression three times more likely to receive opioid medications

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News